![]() ![]() Both technologies are enormously promising, and in some cases they have already realized their promise and cured diseases. Today, this area, sometimes called genetic medicine, stands upon two technological pillars: gene therapy and gene editing. This has opened the possibility of creating therapies that not only treat previously untreatable disease but might also cure patients for life with a single treatment. Recently, scientists and doctors have gained the power to add and subtract tiles from our genomic mosaic. Every year the number of human genomes that have been sequenced increases, as does our understanding of how genes provide the instructions to make us healthy or unhealthy human beings. About 60,000 other genetic sites are significantly associated with traits and diseases such as body mass, cardiovascular disease, neurological conditions, metabolic diseases, immune responses, and many cancers. These include the cystic fibrosis transmembrane receptor, which when mutated causes cystic fibrosis, which can severely damage the lungs and other organs to the point of being life-threatening. Development, homeostasis, and reproduction aging, disease, and death-all are driven by the activity of genes.ĭoctors know of about 4,000 genes that directly cause diseases. Specific sequences of base pairs encode genes, which serve every function in our bodies. These represent the code of life and give rise to the complex phenomena that define health and disease. It is composed of base pairs, the nucleobases A, C, T, and G-the building blocks of DNA. SWFI is a minority-owned organization.Our genome is a mosaic that has evolved over millennia. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. All material subject to strictly enforced copyright laws. No affiliation or endorsement, express or implied, is provided by their use. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. Sovereign Wealth Fund Institute® and SWFI® are registered trademarks of the Sovereign Wealth Fund Institute. © 2008-2023 Sovereign Wealth Fund Institute. By changing any base pair to another, making small insertions or deletions, and writing entire genes into the genome, Gene Writing unlocks the potential to cure genetic diseases and create life-changing therapeutics in cardiovascular, oncological, neurodegenerative, and infectious diseases.Īltitude Life Science Ventures is a venture capital firm based in Kirkland, Washington that invests in early stage life science companies. Gene Writing is a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. Tessera Therapeutics was revealed publicly in July 2020 after years being incubated within Flagship Labs. The genetics company raised US$ 230 million in Series B funding from Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, and the Qatar Investment Authority (QIA). Tessera Therapeutics is a Cambridge, Massachusetts-based programmable genetics startup founded by Flagship Pioneering. Sovereign Wealth Funds Back Gene Writing Company Tessera Therapeutics ![]()
0 Comments
Leave a Reply. |